Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.
Department of Gynecology, Shenzhen Second People's Hospital/The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Life Sci. 2023 May 1;320:121558. doi: 10.1016/j.lfs.2023.121558. Epub 2023 Mar 7.
Glioma is the most common tumor of the primary central nervous system, and its malignant phenotype has been shown to be closely related to glioma stem cells (GSCs). Although temozolomide has significantly improved the therapeutic outcome of glioma with a high penetration rate of the blood-brain barrier, resistance is often present in patients. Moreover, evidence has shown that the crosstalk between GSCs and tumor-associated microglia/macrophages (TAMs) affect the clinical occurrence, growth, and multi-tolerance of chemoradiotherapy in gliomas. Here, we highlight its vital roles in the maintenance of the stemness of GSCs and the ability of GSCs to recruit TAMs to the tumor microenvironment and promote their polarization into tumor-promoting macrophages, hence providing groundwork for future research into new treatment strategies of cancer.
神经胶质瘤是原发性中枢神经系统最常见的肿瘤,其恶性表型已被证明与神经胶质瘤干细胞(GSCs)密切相关。替莫唑胺虽然显著提高了血脑屏障穿透率高的神经胶质瘤的治疗效果,但患者常出现耐药性。此外,有证据表明,GSCs 与肿瘤相关的小胶质细胞/巨噬细胞(TAMs)之间的串扰影响神经胶质瘤的临床发生、生长和放化疗的多耐受性。在这里,我们强调了它在维持 GSCs 的干性和 GSCs 招募 TAMs 进入肿瘤微环境并促进其极化成为促肿瘤巨噬细胞方面的重要作用,为未来研究癌症的新治疗策略提供了基础。